A study in JAMA Network Open examined the acute adverse effects of therapeutic doses of psilocybin for treating depression and anxiety, focusing on its safety profile by assessing the occurrence of immediate side effects like headache, nausea, and elevated blood pressure among others.
The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal.
Patients on psilocybin for depression or anxiety reported tolerable adverse events, including headache, nausea, anxiety, dizziness, and elevated blood pressure.